* Positive top-line results from cancer drug phase II study
* Says it shows potential for treatment of front line NHL
* Positive results just nine days after drug disappointed
By Teis Jensen
COPENHAGEN, Aug 26 (Reuters) - The Danish biotech company Genmab said on Wednesday that it got positive top-line results from a phase II study of its Arzerra cancer drug, which is being co-developed with GlaxoSmithKline....
AJHO: The American Journal of Hematology/Oncology
August 18, 2009
● RESEARCHERS OF THE CHILDREN'S ONCOLOGY GROUP HAVE DEVELOPED a new chemotherapy regimen known as ABVE-PC to treat patients with pediatric Hodgkin lymphoma (HL). Led by Cindy Schwartz, MD, director of pediatric hematology/ oncology at Hasbro Children's Hospital in Providence, Rhode Island, the group combined six different drugs into a dose-dense regimen that achieves rapid early response and limits...
NEW YORK AUG 19, 2008 (Reuters Health) - Women with high-risk gestational trophoblastic neoplasia, as well as those who fail initial single-agent therapy, should be referred to a specialized trophoblastic disease center to maximize the chance for cure, physicians at Northwestern University in Chicago recommend.
Gestational trophoblastic neoplasia is one of the most curable of all human tumors, Dr. John R. Lurain and colleagues note in the August issue of Obstetrics & Gynecology....
Novel Treatments Show Improvements In Survival And Response Rates For Leukemia And Lymphoma
ScienceDaily (Dec. 6, 2008) — The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse according to study results being presented on Saturday, December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.
NEW YORK—A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D., of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology (abstract).
